Results 331 to 340 of about 602,416 (352)
Some of the next articles are maybe not open access.
Xenobiotica; the fate of foreign compounds in biological systems, 2019
Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor (DXd) at a drug-to-antibody ratio (DAR) of 7-8 ...
Y. Nagai +3 more
semanticscholar +1 more source
Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor (DXd) at a drug-to-antibody ratio (DAR) of 7-8 ...
Y. Nagai +3 more
semanticscholar +1 more source
The antibody–drug conjugate landscape
Nature reviews. Drug discoveryPatrick M. Flynn +4 more
semanticscholar +1 more source
Multifunctional biocatalyst for conjugate reduction and reductive amination
Nature, 2022Thomas W Thorpe +2 more
exaly
Hodgkin lymphoma: A review and update on recent progress
Ca-A Cancer Journal for Clinicians, 2018Satish P Shanbhag, Richard F Ambinder
exaly
Application of Nanotechnology in Cancer Therapy and Imaging
Ca-A Cancer Journal for Clinicians, 2008Dong M Shin
exaly
Polymer–drug conjugate therapeutics: advances, insights and prospects
Nature Reviews Drug Discovery, 2018Iriny Ekladious +2 more
exaly